- Home
- EMX vs BWAY Comparison
EMX vs BWAY Comparison
Compare EMX & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMX
- BWAY
- Stock Information
- Founded
- EMX N/A
- BWAY 2003
- Country
- EMX Canada
- BWAY Israel
- Employees
- EMX N/A
- BWAY N/A
- Industry
- EMX
- BWAY Medical/Dental Instruments
- Sector
- EMX
- BWAY Health Care
- Exchange
- EMX Nasdaq
- BWAY Nasdaq
- Market Cap
- EMX 232.8M
- BWAY 207.4M
- IPO Year
- EMX N/A
- BWAY 2019
- Fundamental
- Price
- EMX $2.25
- BWAY $9.14
- Analyst Decision
- EMX Strong Buy
- BWAY Strong Buy
- Analyst Count
- EMX 1
- BWAY 3
- Target Price
- EMX $5.00
- BWAY $13.17
- AVG Volume (30 Days)
- EMX 572.1K
- BWAY 34.0K
- Earning Date
- EMX 05-12-2025
- BWAY 05-07-2025
- Dividend Yield
- EMX N/A
- BWAY N/A
- EPS Growth
- EMX N/A
- BWAY N/A
- EPS
- EMX N/A
- BWAY 0.06
- Revenue
- EMX $27,448,000.00
- BWAY $41,016,000.00
- Revenue This Year
- EMX N/A
- BWAY $349.63
- Revenue Next Year
- EMX $9.92
- BWAY $27.16
- P/E Ratio
- EMX N/A
- BWAY $58.88
- Revenue Growth
- EMX 3.11
- BWAY 29.04
- 52 Week Low
- EMX $1.59
- BWAY $4.72
- 52 Week High
- EMX $2.30
- BWAY $11.79
- Technical
- Relative Strength Index (RSI)
- EMX 65.58
- BWAY 53.17
- Support Level
- EMX $2.13
- BWAY $7.84
- Resistance Level
- EMX $2.18
- BWAY $9.24
- Average True Range (ATR)
- EMX 0.09
- BWAY 0.52
- MACD
- EMX 0.02
- BWAY 0.11
- Stochastic Oscillator
- EMX 88.83
- BWAY 92.86
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.